A Phase 2 interventional study of insulin glargine and human insulin in Pemphigus Vulgaris, Skin Erosion and Autoimmune Blistering Disease, sponsored by Alexandria University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Alexandria University · Phase 2, Interventional, and Treatment
This study investigates the efficacy of topical insulin in promoting healing of pemphigus vulgaris erosions. Twenty patients with pemphigus vulgaris were enrolled, each contributing three comparable lesions randomly allocated to receive long-acting insulin (insulin glargine), short-acting insulin (regular insulin), or normal saline control. Treatments were applied topically twice daily for 14 days or until complete healing.
76 studies on the registry are indexed under Pemphigus; 18 are open to participants now.
This study's enrollment of 20 is below the median of 30 across 53 interventional studies indexed under Pemphigus.
Browse Pemphigus studies →Alexandria University is the lead sponsor of 604 studies on the registry; 140 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Lesions treated with topical insulin glargine (Lantus) 0.1 mL per 10 cm² twice daily
Drug: insulin glargine
Lesions treated with topical regular insulin (Actrapid) 0.1 mL per 10 cm² twice daily
Drug: human insulin
Lesions treated with topical 0.9% normal saline 0.1 mL per 10 cm² twice daily
Drug: 0.9% Normal Saline
Topical application of insulin glargine (100 IU/mL) at dose of 0.1 mL per 10 cm² lesion area, applied twice daily using insulin syringe spray technique for 14 days or until complete healing
Also known as: lantus
topical application of regular insulin (100 IU/mL) at dose of 0.1 mL per 10 cm² lesion area, applied twice daily using insulin syringe spray technique for 14 days or until complete healing
Also known as: actrapid
Topical application of 0.9% normal saline at dose of 0.1 mL per 10 cm² lesion area, applied twice daily using insulin syringe spray technique for 14 days or until complete healing
Also known as: control, placebo
Time to Complete Healing
Number of days required for complete epithelialization of the lesion
Time frame: Up to 14 days
Lesion Surface Area Reduction
Percentage reduction in lesion surface area from baseline,Measured using ImageJ software from standardized photographs
Time frame: Baseline, Day 7, Day 14
Daily Healing Rate
Percentage of healing per day,Calculated as percentage of surface area reduction per day
Time frame: 14 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in Aug 2025, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Glargine · Insulin, Regular, Human